Overview and Scope
Intestinal pseudo-obstruction (IPO) treatment refers to treating a rare gastrointestinal motility disorder characterized by symptoms similar to a mechanical bowel obstruction despite the absence of a physical blockage. The treatment of intestinal pseudo-obstruction aims to alleviate symptoms, improve intestinal motility, manage complications and improve the overall quality of life.
Sizing and Forecast
The intestinal pseudo-obstruction treatment market size has grown strongly in recent years. It will grow from $22.06 billion in 2023 to $23.46 billion in 2024 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increased recognition and diagnosis, advancements in medical imaging, advancements in gastrointestinal motility testing, global healthcare access.
The intestinal pseudo-obstruction treatment market size is expected to see strong growth in the next few years. It will grow to $29.04 billion in 2028 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period can be attributed to research and drug development, telemedicine and remote monitoring, patient education and support, reimbursement policies. Major trends in the forecast period include advanced gastrointestinal motility testing, immunomodulatory therapies, nutritional interventions, data analytics and ai.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/intestinal-pseudo-obstruction-treatment-global-market-report
Segmentation & Regional Insights
The intestinal pseudo-obstruction treatment market covered in this report is segmented –
1) By Drug Class: Antibiotics; Antidepressants; Antidiarrheals
2) By Treatment: Medication; Surgery; Diet; Decompression; Other Treatments
3) By Route Of Administration: Oral; Intravenous; Other Route Of Administrations
4) By Diagnosis: Physical Examination; Biopsy; Blood Test; Gastric Emptying Tests; Imaging Tests; Other Diagnosis
5) By End User: Clinic; Hospitals; Other End Users
North America was the largest region in the intestinal pseudo-obstruction treatment market in 2023. The regions covered in intestinal pseudo-obstruction (IPO) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12995&type=smp
Major Driver Impacting Market Growth
The rising cases of Parkinson’s disease are expected to propel the growth of the intestinal pseudo-obstruction treatment market going forward. Parkinson’s disease refers to a neurodegenerative condition that primarily affects the dopamine-producing neurons in the substantia nigra, a particular region of the brain. There is an increased incidence of IPO in individuals with Parkinson’s disease because it affects the enteric nervous system, causing gastrointestinal dysmotility that can result in megacolon or intestinal blockage, including acute colonic pseudo-obstruction. For instance, in December 2022, according to the Parkinson’s Foundation, a US-based non-profit group, Parkinson’s disease (PD) was identified in roughly 90,000 Americans annually, compared to the previous estimate of 60,000 diagnoses annually, there has been a sharp 50% increase. In addition, it is predicted that by 2030, there will be 1.2 million people worldwide with Parkinson’s disease. Therefore, the rising cases of Parkinson’s disease drive the growth of the intestinal pseudo-obstruction treatment market.
Key Industry Players
Major players in the intestinal pseudo-obstruction treatment market are F. Hoffmann-La Roche AG, Merck Sharp & Dohme Corp, Bayer AG, Sanofi S.A., AstraZeneca PLC, GSK PLC, Takeda Pharmaceutical Company Limited, Amgen PLC, Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Mylan N.V., Biogen Inc., Penn Medicine, Sun Pharmaceutical Industries Ltd., Aurobindo Pharma Ltd., Cipla Inc., Dr. Reddy’s Laboratories Ltd., Allergan PLC, Torrent Pharmaceuticals Limited, Basilea Pharmaceutica Ltd., Paratek Pharmaceuticals Inc., Melinta Therapeutics LLC, Tetraphase Pharmaceuticals Inc., Callisto Pharmaceuticals Inc.
The intestinal pseudo-obstruction treatment market report table of contents includes:
1. Executive Summary
- Intestinal Pseudo Obstruction Treatment Market Characteristics
- Intestinal Pseudo Obstruction Treatment Market Trends And Strategies
- Intestinal Pseudo Obstruction Treatment Market – Macro Economic Scenario
- Global Intestinal Pseudo Obstruction Treatment Market Size and Growth
. - Global Intestinal Pseudo Obstruction Treatment Market Competitive Benchmarking
- Global Intestinal Pseudo Obstruction Treatment Market Competitive Dashboard
- Key Mergers And Acquisitions In The Intestinal Pseudo Obstruction Treatment Market
- Intestinal Pseudo Obstruction Treatment Market Future Outlook and Potential Analysis
- Appendix
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
